Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2009 Oct;45(10):731-5. doi: 1396674/dot.2009.45.10.1416583.

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.

Author information

  • Division of Applied Medicine, Institute of Medical Science, University of Aberdeen, Foresterhill, Aberdeen, UK. g.m.walsh@abdn.ac.uk

Abstract

Familial cold-induced autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease make up cryopyrin-associated periodic syndromes (CAPS). These are autoinflammatory inherited disorders caused by autosomal dominant gain-of-function mutations in the NLRP3 gene, located on chromosome 1q44. Cryopyrin/NALP3/NLRP3 is an essential component of intracellular inflammasomes that activate caspase-1, which in turn converts interleukin-1beta (IL-1beta) to its active form. IL-1beta is a potent cytokine that activates diverse elements of the immune and inflammatory systems leading to the pathogenic changes characteristic of CAPS. There is therefore much interest in the development of IL-1beta blocking agents as novel biologic treatments for these conditions. Canakinumab (ACZ-885; Ilaris, Novartis Pharma) is a fully humanized monoclonal antibody (mAb) specific for IL-1beta and is indicated for a wide range of inflammatory disorders including CAPS. This review will assess the utility of canakinumab as a treatment for CAPS.

Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

PMID:
20069137
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Prous Science
    Loading ...
    Write to the Help Desk